Subtype
Uterine Neoplasm
CI-CAN-00004208Explore in graph →
Non-malignant925 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004208Explore in graph →
Clinical trials
3,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07743541 | Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy(NAPISTAR 1-03) | not yet recruiting | Phase 1 / Phase 2 | 100 | Tubulis GmbHINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | active not recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 |
| clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT07738315 | Elemene Liposomes in Endometrial Cancer | not yet recruiting | Phase 2 | 212 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT01797523 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03526432 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | active not recruiting | Phase 2 | 110 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT06715241 | A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS(COLIBRI-2) | active not recruiting | Phase 2 | 77 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07737795 | Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 66 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | terminated | Phase 2 | 35 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02912572 | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | active not recruiting | Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07731607 | Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer | not yet recruiting | Phase 2 | 48 | Wang JianliuOTHER | 0 | Jul 28, 2026 | clinicaltrials |
| NCT07731828 | Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial | recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05538897 | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | active not recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05838521 | A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer | recruiting | Phase 2 | 20 | Yale UniversityOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT06529809 | Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | terminated | Phase 1 / Phase 2 | 179 | GenmabINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | terminated | Phase 1 / Phase 2 | 214 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | active not recruiting | Phase 2 | 120 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia(PKUPH-ORLPP-EC) | not yet recruiting | Phase 2 | 48 | Peking University People's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04469764 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | recruiting | Phase 2 | 32 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | completed | Phase 2 | 14 | Thomas Jefferson UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | recruiting | Phase 2 | 270 | Corcept TherapeuticsINDUSTRY | 8 | Jul 16, 2026 | clinicaltrials |
| NCT07209449 | A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | recruiting | Phase 2 | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07139977 | Study of EV for Recurrent Endometrial Carcinoma(EV-4-EC) | recruiting | Phase 2 | 12 | William BradleyOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07693452 | Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms | recruiting | Phase 2 | 15 | University of California, IrvineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03180294 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | completed | Phase 2 | 230 | NRG OncologyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT04774419 | Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery | recruiting | Phase 2 | 62 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07669363 | Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)(Aurora) | not yet recruiting | Phase 2 | 230 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT04527900 | The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach | terminated | Phase 2 | 2 | University of Maryland, BaltimoreOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT00087685 | RAD001 in Recurrent Endometrial Cancer Patients | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05377996 | A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | recruiting | Phase 1 / Phase 2 | 360 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT03832361 | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer | recruiting | Phase 2 | 50 | Alessandro SantinOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2026source: clinicaltrials